Sagimet Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SGMT research report →
Range $7 – $29
Price Chart
About the company
Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
- CEO
- David Happel
- IPO
- 2023
- Employees
- 16
- HQ
- San Mateo, CA, US
Get TickerSpark's AI analysis on SGMT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $288.73M
- P/E
- -6.92
- Fwd P/E
- 10.99
- PEG
- -0.18
- P/S
- 0.00
- P/B
- 1.84
- EV/EBITDA
- -2.51
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -31.96%
- ROIC
- -20.39%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-56,889,000
- Net Income
- $-51,038,000-12.0%
- EPS
- $-1.58-9.0%
- OCF Growth
- -7.6%
- FCF Growth
- -7.6%
- 52W High
- $11.45
- 52W Low
- $4.50
- 50D MA
- $9.79
- 200D MA
- $7.19
- Beta
- 3.49
- RSI (14)
- 39
- Avg Volume
- 1.25M
No earnings-call transcripts are available for SGMT yet.
- Free Float
- 95.8%
- Shares Outstanding
- 32.58M
- Float Shares
- 31.21M
of shares held by institutions
93 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.58M | ▲ 5.78M |
| Balyasny Asset Management L.P. | 3.63M | ▲ 3.63M |
| Woodline Partners LP | 3.00M | ▲ 2.00M |
| Silverarc Capital Management, LLC | 2.93M | ▲ 2.93M |
| Vanguard Capital Management LLC | 2.57M | ▲ 1.47M |
| Bvf Inc/Il | 2.50M | ▲ 2.50M |
| Caligan Partners LP | 2.50M | ▲ 2.50M |
| Affinity Asset Advisors, LLC | 2.50M | ▲ 1.63M |
| Federated Hermes, Inc. | 2.09M | ▲ 2.09M |
| Great Point Partners LLC | 2.03M | ▲ 2.03M |
| State Street Corp | 2.00M | ▲ 1.87M |
| Saturn V Capital Management LLC | 1.48M | ▲ 1.48M |
Held by 144 ETFs
Biggest fund positions in SGMT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | Kemble George | other | 24,369 |
| Aug 14, 26 | Kemble George | other | 326,618 |
| Aug 14, 26 | Kemble George | sell | 350,987 |
| Aug 14, 26 | Kemble George | other | 326,618 |
| Aug 14, 26 | Kemble George | other | 24,369 |
| Aug 11, 26 | Kemble George | other | 9,751 |
| Aug 11, 26 | Kemble George | other | 10,455 |
| Aug 11, 26 | Kemble George | other | 9,751 |
| Aug 11, 26 | Kemble George | sell | 20,206 |
| Aug 11, 26 | Kemble George | other | 10,455 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SGMT coverage
Recent articles, reports, and earnings notes.
No research on SGMT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SGMT report →Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Reaffirmed as “Buy” by HC Wainwright
defenseworld.net · Oct 5
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
defenseworld.net · Oct 4
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
marketbeat.com · Oct 3
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
globenewswire.com · Oct 1
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
seekingalpha.com · Sep 30
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
benzinga.com · Sep 30
Sagimet posts 52-week denifanstat acne data
defenseworld.net · Sep 30
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
globenewswire.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.